Zymergen Zymergen has produced a billion pounds of bio-based products, and they’re just getting started. CEO and co-founder Josh Hoffman sat down with me to talk about the future of the bioeconomy. ZYMERGEN
Home » Biomanufacturing, chemicals & materials » If Software Is Eating The World, Biology Is Going To Rebuild It: Zymergen CEO Josh Hoffman On The Coming Bioeconomy

If Software Is Eating The World, Biology Is Going To Rebuild It: Zymergen CEO Josh Hoffman On The Coming Bioeconomy

In their 2019 book “The Making of a Democratic Economy,” Marjorie Kelly and Ted Howard pose a provocative question: Why not use the U.S. Federal Reserve System to buy up all the nation’s oil companies and close them down? The goal: to dramatically decelerate climate change and jump-start policy and investment in sustainable energy.

This may sound like an absurd idea with a hefty check (the top ten U.S. oil companies are valued at about $500 billion). However, the U.S. government has committed to spending over $6 trillion on the coronavirus crisis, and that number could go higher. What if we spent the same amount to prevent the climate crisis?

I sat down with Josh Hoffman, the CEO and co-founder of Zymergen, to ask him this and other questions to get his perspective on the emerging bioeconomy. If you haven’t heard of Zymergen before, it manufactures microbes for Fortune 500 companies. Utilizing a combination of biology, machine learning, and automation, its products range from materials (see my earlier article about the novel material Hyaline used in the electronics industry) to agricultural solutions, to personal care products.

Can we talk about the oil industry? What do you think of the bold idea to buy out the industry in California and pay them to simply leave the oil in the ground?

It’s important to take a historical perspective. Human welfare has increased incredibly because of the ingenuity of cracking and using hydrocarbons. Modern materials, modern medicine – all these things are outgrowths of the petrochemical industry. I think it’s important to recognize that.

It’s also important to recognize that these advances in human welfare have also come with a list of problems we now need to solve. For example, increased agricultural productivity means that we can feed the world, but it also means that many people are now morbidly obese, and the amount of people suffering from diabetes has increased to a point at which it never was before. And there has to be a fierce urgency to solve these problems now.

Our planet is on fire. Climate change is the biggest existential threat. And in a moment like this, with COVID-19, it is easy to forget all of these problems.

I love the poetry of keeping the oil in the ground—it’s a wonderful idea to think about. But it is wholly impractical. So many things we need and use today comes from oil and gas, and I think we need to figure out a transition. The way we think about transition at Zymergen is to give people better products.

Here is a real lesson from the first-generation biofuels companies: the market is not going to pay you for the sake of being green. But they will pay for something better. So our approach is, “How do we make things that are better and disrupt the economics of petroleum?”

Hyaline—Zymergen’s new bioelectronic material—seems like a good example of this. Can you tell me why it’s better than its conventional counterparts?

First, let’s compare petrochemistry to biology. If you crack a hydrocarbon, you will get around 15 intermediates, maybe a couple of hundred base monomers, and a limited number of polymers.

Biology gives you orders of magnitude more, and those chemicals look different. In manufacturing, think of petrochemistry like a black & white silent film, and biology like multichannel, live streaming, interactive entertainment. It’s a complete step-change in not just the quantity but also the quality of products you can make. Biology lets you solve problems we couldn’t even imagine solving with conventional chemistry. It’s the most powerful manufacturing platform on the planet.

Now, let’s look at Hyaline. It’s a colorless film that is used to make electronics like smartphones, laptops, watches, and televisions. It is a fundamental product innovation in a $10 to $12 billion market that hasn’t seen this kind of innovation in 50 years. It’s a better product that allows a greater density of printed flexible circuits, better touchscreens, and more resilient products with superior properties, in one of the most demanding markets on the planet. By starting with biology, we are able to do things that were unimaginable before.

So Hyaline is a completely new molecule that you designed?

Hyaline is the film, and the film is based on a proprietary monomer. But again, if I show up at a cell phone manufacturer and tell them I have an amazing biology, they’ll say they don’t care. Even if I say I have an amazing monomer or polymer, they won’t necessarily care. But if I have a film that solves a problem, then I am meeting the customer where they are. We have to solve their problems. For anyone to make money on a product, you have to sell them something that solves a problem. No one cares about the molecule itself, or whether it’s made with biology or not. They care about the problems it solves. That’s how biology will disrupt petroleum.

If you were on Gavin Newsom’s task force looking for medium to long term policies to set California on the right path for the next 50 years, what policy recommendations would you make to him?

First, I would continue investment in the UC (University of California) system. The Bay Area has top universities that are truly world-class and you cannot underestimate the value of that. I think it is important that the state does not lose its distinctiveness that comes from having these top universities.Another might be a state-mandated purchasing of bio-based goods, like the USDA BioPreferred program. The goal of a BioPreferred Program is to create market incentives that encourage manufacturers to use sustainable goods in their supply chains, and also spur innovation by reducing market uncertainty. Imagine that the Department of Education needs to buy carpets. Where there’s a bio-based carpet that performs as well or better than conventional carpet at a comparable price, the BioPreferred Program would mandate purchasing the bio-based product. This would be a simple, effective way to help establish the biomanufacturing industry. A California BioPreferred policy is something I would love to see, it sounds like a wonderful idea.Third is housing costs. It is very expensive to live in this area and hard to get people to come work here. I especially worry about young people being able to come and work here.

What do you think of Marc Andreessen’s piece, “It’s Time to Build,” and the role of the VC community in the bioeconomy specifically?

I think there is a tension between what Marc writes and reality. VCs look for a five-year path to liquidity. Five years to invest, five years of return, and one year of extensions, so eleven years at most. That timeline is tough for some of the markets that Marc is talking about. I think it’s an admirable spirit, but I d0n’t know what you do with it.

If you want to build stuff, you need to know something about the real economy. You need to make sure you have time horizons that allow you to invest, and that you’re not necessarily investing against previous patterns, like seeking the Uber of haircuts or the SAS of human resources. There is a wall of capital out there, and we need places to put the money. But we need to get away from the recursive problem of “I need to see a path to exit in five years.”

Take Salesforce as an example. Marc Benioff created the most successful enterprise software company of the decade. Do you know who the VCs were? Nobody, because Marc couldn’t get anybody to write the check. It was an unlikely idea with a very different model. I believe the same is true for the bioeconomy: big disruptive platforms tend to be stuff that falls outside of what mainstream venture firms do. We are all comfortable doing what others have done, but it’s pretty lonely to be out there doing your own thing.

What advice would you give to somebody trying to raise capital in the bioeconomy?

What we did well at Zymergen was to find ways to generate revenue early. Validate your product or service early. Also, be sure to play the long game. This is a slow and steady race. Don’t hype yourself up too much and raise money on unsustainable plans.

If software is eating the world, biology is going to rebuild it. It’s going to take time rebuilding the world with biology, so don’t go out there saying you can do magic.

To learn more about the growing bioeconomy, read my previous articles on McKinsey’s $4 trillion bioeconomy report and the five sectors set to be disrupted by synthetic biology.  

Follow me on Twitter at @johncumbers and @synbiobetaSubscribe to my weekly newsletters in synthetic biology. Thank you to Stephanie Michelsen and Kevin Costa for additional research and reporting in this article. I’m the founder of SynBioBeta, and some of the companies that I write about—including Zymergen—are sponsors of the SynBioBeta conference and weekly digest. Here’s the full list of SynBioBeta sponsors

1
John Cumbers

John Cumbers

John Cumbers is the founder of SynBioBeta. John is passionate about education and on the use and adoption of biological technologies. He has received multiple awards and grants from NASA and the National Academy of Sciences for his work in the field. John has been involved in multiple startups such as those producing food for space, microbes to extract lunar and martian resources, and hoverboards! John is an active investor through the DCVC SynBioBeta Fund and his synthetic biology syndicate on AngelList.

Stephanie Michelsen

Stephanie Michelsen

Stephanie Michelsen is pursuing her M.Sc. in Biotechnology at the University of Copenhagen, Denmark. She recently got accepted as an International Innovation Program (2ip) fellow, a program designed to connect Danish life science students with the biotech start-up industry in the Bay Area. She is therefore currently living in the San Francisco Sunset district with four other Danish students learning about biotech entrepreneurship. As a 2ip fellow and as a writer and editor for SynBioBeta she is fortunate enough to further explore her interest in the many possibilities of synthetic biology.

Kevin Costa

Kevin Costa

As Editor and Program Manager, Kevin leads SynBioBeta's digital media content, with the goal of telling the story of the people, companies, and ideas shaping the future with biology. Before joining SynBioBeta, Kevin managed the Synthetic Biology Engineering Research Center. His interests include public engagement, science writing, community building, and bikes!

Click here to join our weekly newsletter. We want to hear what you think about this article. Got a tip for our news team? Write to editorial@synbiobeta.com.

Editor’s picks